Investors
Investment Summary
Magellan Stem Cells aims to be the world first and leading supplier of off-the-shelf allogeneic stem cell therapy in the treatment of Osteoarthritis
Magellan Stem Cells product MAG200 is an exciting investment opportunity for strategic investors, addressing a global and currently unmet medical need. Our 13 years of intensive research which includes pre-clinical research and Phase 1-2 trials for clinical safety and efficacy, our product MAG200 has been developed as an off-the-shelf allogeneic stem cell treatment for osteoarthritis.
In the fourth quarter of 2023, Magellan Stem Cells product MAG200 will enter a pivotal P3 clinical trial. Our trial synopsis has been reviewed and accepted by the TGA. This phase presents a prime opportunity for investors who value emerging technologies in biomedical research.
With unique proprietary information and intellectual property, supported by strong patent portfolio protection, Magellan Stem Cells product MAG200 is a scalable global treatment with the potential for significant market penetration.
Investment Opportunity
Magellan Stem Cells is looking for like-minded investment partners
We are in strategic discussions with interested investors and offering a minority interest in Magellan Stem Cells. We are looking for significant investment to help support the P3 clinical trial.
There is a very large potential international market for an efficacious treatment of osteoarthritis
More than 100 million people have in Europe, UK, USA, Canada, Japan and Australia are suffering from osteoarthritis
The estimated cost of an approved product MAG200 treatment is less than 20% of the cost of joint replacement
Magellan Stem Cells is expecting to generate substantial and increasing revenues from 2026 onwards and is projecting a positive EBITDA in the first year of commercial sales.
Board of Directors
Lou Panaccio
Non-Executive Chairman
Mr Panaccio is a Chartered Accountant with a wealth of executive management experience in business and healthcare services. Mr Panaccio has been the Chief Executive Officer of Monash IVF and Executive Director of Melbourne Pathology. He was also a Non-executive Director of ASX-listed Genera Biosystems Limited.
Mr Panaccio currently holds positions on the boards of ASX and NASDAQ listed Avita Therapeutics Inc. ASX50 company Sonic Healthcare Limited, ASX-listed Rhythm Non-executive Director.
Peter Hansen
Ross Williams
Michael Kenihan
Julien Freitag
Management Team
Kiran Shah
Julien Freitag
Richard Price
Renee Castelluccio
Next Steps
We welcome your interest and enquiries in investing in Magellan Stem Cells and its product MAG200 in preparation for P3 trial. Following is an outline of the steps involved to secure your investment.
- Complete Non-Disclosure Agreement
- Supply and review of Information Memorandum
- Confirm Expression of Interest and Key Terms
- Invitation to Data Room
- Detailed Q&A
- Review Legal Documentation
- Complete Negotiations and Finalise Agreements
- Execute Capital Transaction
- Announcement of Phase III definitive trial registration